JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα
2013
The acquired gain-of-function V617F mutation in the Janus Kinase 2 (JAK2V617F) is the main mutation involved in BCR/ABL-negative myeloproliferative neoplasms (MPNs), but its effect on hematopoietic stem cells as a driver of disease emergence has been questioned. Therefore, we reinvestigated the role
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
50
References
94
Citations
NaN
KQI